Musculoskeletal Symptoms in Post Acute Covid-19 Patients

Musculoskeletal Symptoms and Related Factors in Post Acute Covid-19 Patients

The patients whose musculoskeletal symptoms initiated or aggravated with Covid-19, were compared with the patients whose musculoskeletal symptoms did not change with Covid-19. The variables; the demographic and treatment datas, admission symptoms, post acute-Covid-19 symptoms, laboratory, chest computed tomography findings.

Study Overview

• Status: Completed
• Conditions: Covid19; Musculoskeletal Abnormalities
• Intervention / Treatment: Other: Survey; Other: Laboratory parameters; Other: chest computed tomography

Detailed Description

There is a lack of an overview of the factors associated with post acute-Covid-19 musculoskeletal symptoms. The aims are;1-to evaluate the most frequent admission symptoms and the frequency of musculoskeletal symptoms in post acute-Covid-19 patients,2-to determine the related factors with the post acute-Covid-19 musculoskeletal symptoms.

In this retrospective study; the patients whose musculoskeletal symptoms initiated or aggravated with Covid-19, were compared wthe patients whose musculoskeletal symptoms did not change with Covid-19. The variables; the demographic and treatment datas, admission symptoms, post acute-Covid-19 symptoms, laboratory (complete blood count, C-reactive protein, ferritin, D-dimer), chest computed tomography findings.

• Study Type: Observational
• Enrollment (Actual): 280

Contacts and Locations

Study Locations

• Turkey
  • Eskişehir, Turkey
    • Eskişehir City Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

This retrospective cross-sectional study was carried out with the records of 280 post Covid-19 patients who admitted to the physical medicine and rehabilitation outpatient clinic between December 2020 and May 2021.

Description

Inclusion Criteria:

• Being 18 years or older
• Having Covid-19 treatment (home quarantine / hospital / intensive care unit) according to a positive polymerase chain reaction (PCR) test in a nasopharyngeal + oropharyngeal swab or chest CT.

Exclusion Criteria:

• Patients who did not have musculoskeletal symptom records (admission symptoms and musculoskeletal symptoms such as; fatigue, spine / joint /muscle pain/ numbness) in patients files
• Acute Covid-19 patients whose symptoms started less than 1 month

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Change; the patients whose musculoskeletal symptoms initiated or aggravated with Covid-19 (n=240)	Other: Survey; A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease…), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc…, treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.; Other: Laboratory parameters; The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.; Other: chest computed tomography; Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).
No change; the patients whose musculoskeletal symptoms did not change with Covid-19 (n=40)	Other: Survey; A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease…), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc…, treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.; Other: Laboratory parameters; The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.; Other: chest computed tomography; Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of back pain	given as percentage %	Baseline
Chest computed tomography	Presence of covid-19 findings in chest computed tomography (covid findings positive or negative)	Baseline
Rate of low-back pain	given as percentage %	Baseline
Rate of fatigue	given as percentage %	Baseline
Rate of neck pain	given as percentage %	Baseline
Rate of dyspnea	given as percentage %	baseline
Rate of joint pain	given as percentage %	Baseline
Rate of chest pain	given as percentage %	Baseline
Rate of myalgia	given as percentage %	Baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
age	years	Baseline
Weight	kilograms	Baseline
gender	female or male	Baseline
Duration after the onset of covid-19	months	Baseline
Lymhocyte levels	10*3 cells/microliter	Baseline
D-dimer levels	miligram/Litre	Baseline
C-reactive protein	miligram/Litre	Baseline
Hemoglobin	gram/desilitre	Baseline
Platelet	10*3 cells/microliter	Baseline
Ferritin	nanogram/mililitre	Baseline

Collaborators and Investigators

• Sponsor: Eskisehir City Hospital

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 11, 2021
• Primary Completion (ACTUAL): June 13, 2021
• Study Completion (ACTUAL): June 14, 2021

Study Registration Dates

• First Submitted: June 14, 2021
• First Submitted That Met QC Criteria: June 18, 2021
• First Posted (ACTUAL): June 21, 2021

Study Record Updates

• Last Update Posted (ACTUAL): June 21, 2021
• Last Update Submitted That Met QC Criteria: June 18, 2021
• Last Verified: June 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; Congenital Abnormalities; Musculoskeletal Diseases; COVID-19; Musculoskeletal Abnormalities
• Other Study ID Numbers: EskisehirCityH

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: one year later, after my manuscript publishes in a journal.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No